Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00506519
Status:
TERMINATED
Last Update Posted:
2021-08-31
First Post:
2007-07-23
Brief Title:
Recombinant Human Antithrombin ATryn in the Treatment of Patients With DIC Associated With Severe Sepsis
Sponsor:
LEO Pharma
Organization:
LEO Pharma
Study Overview
Official Title:
Exploratory Efficacy and Safety Pharmacokinetics and Dose Finding Study of ATryn Antithrombin Alfa in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis
Status:
TERMINATED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to explore the efficacy and safety of ATryn antithrombin alfa for the treatment of disseminated intravascular coagulation DIC associated with severe sepsis when administered by continuous intravenous IV infusion over five days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None